The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $37.41

Today's change-0.60 -1.58%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $37.41

Today's change-0.60 -1.58%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Abbott Laboratories down (U.S.)$0.60

Abbott Laboratories closed sharply lower Friday, dropping (U.S.)$0.60 or 1.58% to (U.S.)$37.41. Over the last five days, shares have lost 1.16% and sit 3.92% above their 52-week low. This security has underperformed the S&P 500 by 9.20% during the last year.

Key company metrics

  • Open(U.S.) $38.23
  • Previous close(U.S.) $38.01
  • High(U.S.) $38.35
  • Low(U.S.) $37.12
  • Bid / Ask-- / --
  • YTD % change-16.70%
  • Volume5,750,213
  • Average volume (10-day)10,124,726
  • Average volume (1-month)7,953,652
  • Average volume (3-month)7,304,778
  • 52-week range(U.S.) $36.00 to (U.S.) $51.74
  • Beta0.98
  • Trailing P/E21.61×
  • P/E 1 year forward17.35×
  • Forward PEG1.85×
  • Indicated annual dividend(U.S.) $1.04
  • Dividend yield2.78%
  • Trailing EPS(U.S.) $1.73
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.77%

Based on its net profit margin of 12.77%, Abbott Laboratories is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue5,1885,1505,1704,897
Total other revenue--------
Total revenue5,1885,1505,1704,897
Gross profit2,9822,9412,9522,817
Total cost of revenue2,2062,2092,2182,080
Total operating expense4,3794,4374,4414,287
Selling / general / administrative1171,6401,7271,730
Research & development365338345313
Depreciation / amortization143151151156
Interest expense (income), net operating--------
Unusual expense (income)1,54899--8
Other operating expenses, total--------
Operating income809713729610
Interest income (expense), net non-operating-9-41-44-37
Gain (loss) on sale of assets--------
Other--------
Income before tax830714986653
Income after tax695596786529
Income tax, total135118200124
Net income7675807842,292
Total adjustments to net income--------
Net income before extra. items695596786529
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items695596786529
Inc. avail. to common incl. extra. items7675807842,292
Diluted net income7675807842,292
Dilution adjustment--------
Diluted weighted average shares1,4981,5051,5041,516
Diluted EPS excluding extraordinary itemsvalue per share0.460.400.520.35
Dividends per sharevalue per share0.240.240.240.24
Diluted normalized EPSvalue per share1.330.450.520.35